Corporate News Report
In the closing session of the Korean Exchange on Friday, 23 November 2026, Celltrion Inc. (068270.KS) experienced a modest decline of 1.67 %. At 10:11 PM Central Europe, the share price settled at KRW 194,400. The company’s outstanding shares total 232.3 million, yielding a market capitalisation of KRW 45.1 trillion. Over the preceding 24 hours, approximately KRW 101.2 billion worth of shares changed hands.
Trading Context
Despite the recent dip, Celltrion’s performance since the previous month’s close has been positive, registering a 9.53 % increase. The 200‑day simple moving average sits at KRW 189,597.1, comfortably below the current trading level. The stock’s recent high, reached on 24 February 2026, was KRW 239,048, while the 52‑week low of KRW 158,500 was recorded on 8 June 2026. These metrics indicate a healthy upward trajectory over the longer term, even as short‑term volatility persists.
Strategic Development Partnership
A pivotal driver of recent investor sentiment is Celltrion’s announcement of an exclusive global licensing agreement with Kaigene Inc. The collaboration centres on KG‑013, a next‑generation monoclonal antibody engineered to extend half‑life and target the protein APRIL. KG‑013 is designed for subcutaneous, long‑acting administration, potentially reducing dosing frequency for patients with IgA nephropathy—a progressive kidney disease. Under the terms, Celltrion will hold worldwide rights to develop and commercialise the antibody, while Kaigene will receive upfront and milestone payments as well as royalties on sales.
Celltrion’s extensive manufacturing and commercial infrastructure is expected to accelerate the therapy’s clinical development and broaden its therapeutic scope to other IgA‑ and IgM‑mediated autoimmune conditions. The partnership underscores Celltrion’s strategic shift from biosimilars to innovative biologics, positioning the company to capture a growing market for precision immunotherapies.
Market Activity of Peer Companies
The broader Korean market displayed a mixed picture in the same trading window:
| Ticker | Change | Current Price | Market Cap (KRW) | P/E Ratio |
|---|---|---|---|---|
| Shinhan (055550.KS) | –1.53 % | KRW 88,100 | KRW 43.1 trillion | 9.65 |
| Samsung SDI –144a Regs (006400.KS) | –7.58 % | KRW 61,003.27 | KRW 43.1 trillion | — |
| Samsung C&T (028260.KS) | –0.52 % | KRW 288,000 | KRW 46.4 trillion | 20.82 |
| Doosan Enerbility (034020.KS) | –2.99 % | KRW 59,400 | KRW 40.6 trillion | 301.92 |
| Hyundai Mobis (012330.KS) | –2.60 % | KRW 328,500 | KRW 30.6 trillion | 8.8 |
Samsung SDI’s sharp decline mirrored a sector‑wide slide in battery‑related stocks, reflecting investor concerns over quarterly earnings and the profitability of large‑scale AI investments in the semiconductor and battery sectors. Samsung C&T’s modest decline coincided with a high‑profile visit from Samsung Electronics’ executive chairman to its Abu Dhabi power‑plant site, signalling continued investment in Middle‑East infrastructure projects.
Company Overview
Celltrion Inc., headquartered in Inchon‑Si, South Korea, specialises in the development, manufacture, and sale of biosimilar products. The company also offers consignment processing services to external clients. Since its initial public offering on 19 July 2005, Celltrion has grown into a prominent player on the Korea Exchange Stock Market (KRX), maintaining a strong presence in both the biosimilar and biologics sectors.
For further information, interested parties may consult Celltrion’s corporate website at www.celltrion.com .
